Compare UVE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | ABCL |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.9M | 1.1B |
| IPO Year | 1992 | 2020 |
| Metric | UVE | ABCL |
|---|---|---|
| Price | $29.65 | $4.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $7.75 |
| AVG Volume (30 Days) | 210.9K | ★ 4.2M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 70.32 | N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $1,580,798,000.00 | $35,325,000.00 |
| Revenue This Year | $1.87 | $25.45 |
| Revenue Next Year | N/A | $10.07 |
| P/E Ratio | $7.05 | ★ N/A |
| Revenue Growth | 4.61 | ★ 7.17 |
| 52 Week Low | $18.72 | $1.89 |
| 52 Week High | $35.84 | $6.52 |
| Indicator | UVE | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 61.85 |
| Support Level | $29.11 | $4.08 |
| Resistance Level | $31.25 | $4.66 |
| Average True Range (ATR) | 1.13 | 0.25 |
| MACD | -0.39 | 0.11 |
| Stochastic Oscillator | 8.31 | 70.83 |
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.